Interactions of antiarrhythmic drugs and implantable devices in controlling ventricular tachycardia and fibrillation.
Implantable cardioverter defibrillators (ICDs) have proven highly successful in the treatment of life-threatening ventricular arrhythmias. Despite the efficacy of the ICD in terminating ventricular arrhythmias, antiarrhythmic drugs remain an important adjunct to ICD therapy. The use of antiarrhythmic drug therapy in combination with the ICD is synergistic in terms of beneficial effects, but also has the potential for some adverse interactions. Knowledge and recognition of these potential interactions is important for any physician managing patients with an ICD. This review summarizes the benefits and adverse effects of ICD in combination with antiarrhythmic drug therapy, and provides guidelines to ensure safe application of this hybrid therapy.
Rajawat
Yadavendra S
YS
University of Pennsylvania, 3400 Spruce Street, 9 Founders Pavilion, Philadelphia, PA 19104, USA.
Dias
Darryl
D
Gerstenfeld
Edward P
EP
Dixit
Sanjay
S
Shah
Bindi
B
Russo
Andrea M
AM
Marchlinski
Francis E
FE
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017147:Defibrillators, Implantable; D004869:Equipment Safety; D006801:Humans; D017180:Tachycardia, Ventricular / Q000150:complications* / Q000517:prevention & control / Q000628:therapy*; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000150:complications* / Q000517:prevention & control / Q000628:therapy*
D000889:Anti-Arrhythmia Agents